Status:
TERMINATED
The Natural History of Solid Organ Cancer Stem Cells (SOCSC)
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Hepatic Cancer
Pancreatic Ductal Cancer
Eligibility:
All Genders
16-100 years
Brief Summary
Background: * Researchers are trying to learn what causes certain types of cancer to spread to other organs in the body (metastasis). Cancer tumors may produce a very small number of specific cells (...
Detailed Description
Background: * Traditional models of cancer metastasis posit that cancer metastases might originate stochastically in any cancer cell while, the Cancer-Stem-Cell hypothesis suggests that the metastasi...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA: (Beginning with amendment J, all patients must meet the first eligibility criteria a. Patients scheduled to underg
- surgery must meet criteria b-e.)
- Patients with radiographic evidence of, biochemical evidence of, and/or histologically/cytologically proven solid organ cancer, including hepatobiliary cancer, pancreatic cancer, colorectal cancer, gastric cancer, breast cancer, adrenal cancer, mesothelioma, anal cancer, female reproductive tract cancer (ovarian, uterine and cervical), melanoma, and sarcoma.
- Patients with rare solid organ cancers including but not limited to small intestine, vagina, vulva, carcinoid, skin, pediatric cancers, Kaposi s sarcoma, and cancers of unknown origin.
- Patients with premalignant neoplasms who are scheduled to undergo surgery or biopsy as part of their diagnostic evaluation.
- Patients with a family history of familial or hereditary solid organ cancers or a clinical suspicion for a familial cancer (these patients may show no evidence of disease at the time of enrollment).
- Patients must have an ECOG performance score of 0-2.
- Patients must be 16 years of age or older.
- Patients must have laboratory and physical examination parameters within acceptable limits by standard of practice guidelines prior to biopsy or surgery. Note: Not applicable for healthy relatives having blood analyzed for DNA only.
- Patients must be seronegative for HIV antibody, Hepatitis B surface antigen and Hepatitis C antibody, with the exception of patients with hepatocellular cancers, who must be seronegative for HIV antibody only. Note: Not applicable for healthy relatives having blood analyzed for DNA only.
- Patients undergoing treatment for their neoplasm under other current NIH protocols may be eligible.
- Note: Patients will not undergo surgery or biopsy for the sole purpose of tissue procurement.
Exclusion
Key Trial Info
Start Date :
February 9 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 7 2015
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT00923052
Start Date
February 9 2009
End Date
May 7 2015
Last Update
December 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892